{"id":"a-second-dose-with-an-1-year-interval","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, erythema, swelling)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Myalgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This represents a second-dose vaccination schedule with a 12-month interval between the primary and booster doses. The booster is designed to restimulate the immune system and maintain or increase antibody titers and cellular immunity against the target pathogen. This dosing interval is typical for vaccines requiring sustained long-term protection.","oneSentence":"A booster vaccination dose administered one year after initial immunization to maintain or enhance immune protection.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:26:01.273Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Booster vaccination (specific indication unknown without additional product information)"}]},"trialDetails":[{"nctId":"NCT05766046","phase":"NA","title":"Lung Cancer Prevention Screening Programme in Italy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ugo Pastorino","startDate":"2022-09-17","conditions":"Lung Cancer, COPD (Chronic Obstructive Pulmonary Disease) With Acute Lower Respiratory Infection, Cardiovascular Diseases","enrollment":7324},{"nctId":"NCT07174726","phase":"PHASE2","title":"A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa","status":"RECRUITING","sponsor":"Beacon Therapeutics","startDate":"2025-09-10","conditions":"X-Linked Retinitis Pigmentosa (XLRP)","enrollment":10},{"nctId":"NCT04471987","phase":"PHASE1","title":"Safety and Early Signs of Efficacy of IL12-L19L19.","status":"RECRUITING","sponsor":"Philogen S.p.A.","startDate":"2020-07-01","conditions":"Advanced Solid Tumor, Metastatic Solid Tumor","enrollment":80},{"nctId":"NCT05327894","phase":"PHASE3","title":"Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2022-12-15","conditions":"Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia","enrollment":160},{"nctId":"NCT06441331","phase":"PHASE1","title":"Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors","status":"RECRUITING","sponsor":"ITM Solucin GmbH","startDate":"2025-09-26","conditions":"Somatostatin Receptor Positive, NETs, Lymphoma","enrollment":20},{"nctId":"NCT05032976","phase":"","title":"Korea Comirnaty Post-marketing Surveillance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-03-18","conditions":"COVID-19, Vaccines, Adverse Effects","enrollment":12000},{"nctId":"NCT04889209","phase":"PHASE1, PHASE2","title":"Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-05-28","conditions":"COVID-19","enrollment":867},{"nctId":"NCT05313191","phase":"NA","title":"Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors","status":"RECRUITING","sponsor":"The New York Proton Center","startDate":"2022-01-24","conditions":"CNS Cancer, Head and Neck Cancer, GI Cancer","enrollment":1800},{"nctId":"NCT04026009","phase":"PHASE1","title":"Safety and Immunogenicity Study of GSK's Clostridium Difficile Vaccine 2904545A When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-08-05","conditions":"Clostridium Infections","enrollment":140},{"nctId":"NCT02688985","phase":"PHASE3","title":"Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2016-04-29","conditions":"Relapsing Multiple Sclerorsis, Multiple Sclerosis, Primary Progressive","enrollment":131},{"nctId":"NCT06209398","phase":"PHASE4","title":"Immunogenicity of the Inactivated EV71 Vaccine Combined With Hepatitis B and Group A Meningococcal Vaccine","status":"UNKNOWN","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2018-05-24","conditions":"Hand, Foot and Mouth Disease","enrollment":510},{"nctId":"NCT04381936","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2020-03-19","conditions":"Severe Acute Respiratory Syndrome","enrollment":70000},{"nctId":"NCT05444933","phase":"","title":"A Study to Collect Pre-existing Data on the Administration of Cabozantinib in Participants With Advanced Renal Cell Carcinoma (aRCC) Who Initiated Cabozantinib in 2nd Line in a Real-life Clinical Setting in France.","status":"COMPLETED","sponsor":"Ipsen","startDate":"2022-09-16","conditions":"Advanced Renal Cell Carcinoma","enrollment":252},{"nctId":"NCT05715918","phase":"PHASE3","title":"Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19 of Children at the Age of 12-17 Years Inclusive\"","status":"UNKNOWN","sponsor":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products","startDate":"2022-04-01","conditions":"Vaccine","enrollment":300},{"nctId":"NCT05367895","phase":"","title":"Effectiveness of Inactivated COVID-19 Vaccine of the First Booster Dose","status":"UNKNOWN","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-07-30","conditions":"COVID-19","enrollment":14000},{"nctId":"NCT05109559","phase":"PHASE1, PHASE2","title":"Ad26.COV2.S as a Heterologous Booster in Adults After Single- or Two-Dose of Inactivated COVID-19 Vaccine","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2021-12-20","conditions":"SARS-CoV-2 Infection","enrollment":690},{"nctId":"NCT03944447","phase":"PHASE2","title":"Outcomes Mandate National Integration With Cannabis as Medicine","status":"UNKNOWN","sponsor":"OMNI Medical Services, LLC","startDate":"2018-12-01","conditions":"Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury","enrollment":200000},{"nctId":"NCT03581734","phase":"PHASE3","title":"Immunogenicity of Co-administered Oral Polio Vaccine and Oral Cholera Vaccine","status":"UNKNOWN","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2018-07-01","conditions":"Vaccine Reaction","enrollment":579},{"nctId":"NCT01798056","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-03-06","conditions":"Herpes Zoster, Herpes Zoster Vaccine","enrollment":237},{"nctId":"NCT01791114","phase":"NA","title":"The Effect of Brown Adipose Tissue Activation on Insulin Sensitivity in Humans","status":"COMPLETED","sponsor":"Rutgers University","startDate":"2012-01","conditions":"Insulin Sensitivity, Obesity","enrollment":39},{"nctId":"NCT00461097","phase":"PHASE2","title":"Oral Immunotherapy for Childhood Egg Allergy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-05","conditions":"Hypersensitivity, Immediate Hypersensitivity, Food Hypersensitivity","enrollment":55},{"nctId":"NCT00959465","phase":"PHASE1, PHASE2","title":"A/H1N1 Immunogenicity and Safety in Adults","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2009-08","conditions":"Influenza, Pandemic Influenza","enrollment":408},{"nctId":"NCT01171976","phase":"PHASE3","title":"Efficacy and Safety of Ranibizumab in Two \"Treat and Extend\" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-09","conditions":"Diabetic Macular Edema","enrollment":373},{"nctId":"NCT02146469","phase":"PHASE4","title":"Study on Effectiveness of 2-dose Live Attenuated Varicella Vaccine","status":"UNKNOWN","sponsor":"Shanghai Municipal Center for Disease Control and Prevention","startDate":"2012-12","conditions":"Varicella","enrollment":1200},{"nctId":"NCT01579448","phase":"PHASE4","title":"Evaluation of a Boosting Regimen With Oral Cholera Vaccine","status":"COMPLETED","sponsor":"Sachin Desai","startDate":"2012-12","conditions":"Cholera","enrollment":426},{"nctId":"NCT00927862","phase":"PHASE2, PHASE3","title":"Applying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin","status":"COMPLETED","sponsor":"Intermountain Health Care, Inc.","startDate":"2008-08","conditions":"Thromboembolism","enrollment":2415},{"nctId":"NCT00709410","phase":"NA","title":"Mass Oral Cholera Vaccination in Zanzibar","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2009-01","conditions":"Cholera, Diarrhea","enrollment":51151}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"A second dose with an 1 year interval","genericName":"A second dose with an 1 year interval","companyName":"Shanghai Municipal Center for Disease Control and Prevention","companyId":"shanghai-municipal-center-for-disease-control-and-prevention","modality":"Biologic","firstApprovalDate":"","aiSummary":"A booster vaccination dose administered one year after initial immunization to maintain or enhance immune protection. Used for Booster immunization (specific indication unknown without additional product information).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}